期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌靶向药物肝脏毒性作用研究进展 被引量：5

Drug Induced Hepatotoxicity in Targeted Therapy for Lung Cancer
下载PDF
导出
摘要 针对驱动基因的靶向药物吉非替尼、厄洛替尼及克唑替尼等在晚期非小细胞肺癌治疗中有着不可替代的地位,然而此类药物给患者带来益处的同时也出现较高的肝脏毒性,现就其肝脏毒性及机制作一综述。 Targeted drugs aimed at driver gene, such as Geiftinib, Erlotinib and Crizotinib, have an irreplaceable position in the therapy of advanced non-small cell lung cancer. hTese drugs bring beneift to patients, however, higher hepato-toxicity is also presented. Now, drug induced hepatotoxicity and its mechanism are reviewed.
作者 陈雪琴 杨邵瑜 马胜林
机构地区 南京医科大学附属杭州医院(杭州市第一人民医院集团)肿瘤内科
出处 《中国肺癌杂志》 CAS 北大核心 2014年第9期685-688,共4页 Chinese Journal of Lung Cancer
基金 浙江省自然科学基金重点项目(No.LZ13H160001)资助~~
关键词 肺肿瘤 靶向药物 肝脏毒性 Lung neoplasms Targeted drugs Hepatotoxicity
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献31

  • 1D'Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010, 21 (Suppl 5): v116-v119.
  • 2Ozkaya S, Findik S, Dirican A, et al. Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med, 2012, 4( 6): 1035-1038.
  • 3Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA, 2014, 311(19): 1998-2006.
  • 4Li Y, Li Y, Yang T, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One, 2013, 8( 1): e52093.
  • 5Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N EnglJ Med, 2009, 361 (10): 947-957.
  • 6Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010,11(2): 121-128.
  • 7Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
  • 8Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol,2011, 12(8): 735-742.
  • 9HanJY, Park K, Kim Sw, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.J Clin Oncol,2012, 30(10): ll22-ll28.
  • 10Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a rnulticentre, double-blind randomised phase 3 trial. Lancet Oncol, 2012,13(5): 466-475.

同被引文献49

引证文献5

二级引证文献10

中国肺癌杂志
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部